

## Interests Register

### Primary Hyperparathyroidism Advisory Committee

**Publication Date: 30/11/2018**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Terry Aspray	Guideline Committee Member	Direct non-financial (reasonable travel expenses)	Educational grant to attend National Osteoporosis Society Meeting, Birmingham, December, 2016. Internis Pharmaceuticals. No topics within the guideline scope were covered.	12/2016	On application	12/2016	Non-specific  Declare and participate
		Direct financial	Received speaker fees for North East Paediatric Skeletal Health Study Day February 2017, Alexon Pharmaceuticals. No topics within the guideline scope were covered.	02/2017	On application	02/2017	Non-specific  Declare and participate
		Direct financial	Speaker fees for Geriatric Medicine Meeting, Edinburgh, June 2017, Pavilion Publishing and Media Ltd. No topics within the guideline scope were covered.	06/2017	On application	06/2017	Non-specific  Declare and participate
		Direct financial	Participation in a focus group discussion on	03/11/2017	02/11/2017	03/11/2017	Non-specific

			osteoporosis, funded by UCB pharma. However, I am not aware of any drugs relevant to this guideline development.				Declare and participate
		Direct financial	<p>Advice given to UCB Pharmaceuticals on osteoporosis therapies (not related to primary hyperparathyroidism).</p> <p>There were two components to this project:</p> <ol style="list-style-type: none"> <li>1. Advising the company (which does not currently market osteoporosis treatments) about routine care for osteoporosis including ALL treatments: bisphosphonates, denosumab and teriparatide</li> <li>2. The potential for their new agent (romosozumab: A sclerostin antibody) in treating osteoporosis</li> </ol>	14/03/2018	19/04/2018	14/03/2018	<p>Non-specific</p> <p>Declare and participate</p>

			While we have discussed in the committee the role of bisphosphonates in the management of PHPT, this is not a topic which is relevant to my work with UCB.				
Julie Cox	Guideline Committee Member	Direct financial	<p>Company Director (along with my husband, Dr Martin Bailey) of Cox Bailey Medical Ltd. We are the only directors and the company's only source of income is JC's private practice earnings. The company does not produce any products or contract with anyone else.</p> <ul style="list-style-type: none"> <li>- Approximately 10% of JC's clinical practice is private</li> <li>- Approximately 5% of the private practice patients have PHPT</li> </ul>	On application	On application	Ongoing	<p>Specific</p> <p>Declare and participate</p> <p>Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully.</p>
Parijat De	Guideline Committee Member	Direct financial	<p>Previously received speaker and advisory board fees for diabetes and metabolic talks from pharmaceutical industries – Novo, Astra, Janssen, MSD, Sanofi, Besins, Internis, and</p>	2004	On application	Ongoing	<p>Non-specific</p> <p>Declare and participate</p>

			Boehringer. Received no payment from companies manufacturing Cinacalcet or bisphosphonates.				
		Direct financial	Undertakes private practice - Private practice no different to NHS practice - Payment is per patient - See 1% or fewer PHPT patients.	2004	17/07/2017	Ongoing	Specific  Declare and participate  Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully.
Joy Foster	Guideline Committee member	Direct non-financial	Committee member for charity Hypopara UK.	On application	28/02/2018	Ongoing	Specific  Declare and participate
Neil Gittoes	Guideline Committee member (Clinical Lead)	Direct financial	Advisory board work – Shire relating to drug therapy for hypoparathyroidism.	01/2017	On application	Ongoing	Non-specific  Declare and participate
		Direct non-financial	NHSE Policy on Cinacalcet use in Primary Hyperparathyroidism.	2016	On application	2018	Specific  Declare and participate
		Indirect financial	Co-chair, Global Scientific Steering Committee on PARADIGM disease registry for	11/2016	On application	Ongoing	Non-specific  Declare and participate

			hypoparathyroidism – supported by Shire.				
		Direct non-financial	<p>Publications – opinions on primary hyperparathyroidism expressed in peer reviewed publications:</p> <ul style="list-style-type: none"> <li>- Chauhan P, Gittoes NJ, Geberhiwot T . Successful treatment of recurrent renal stones with Cinacalcet in a patient with primary hyperparathyroidism . BMJ Case Rep. 2016 Aug 12;2016. PMID: 27520998</li> </ul> <p>This declaration expires August 2017; no cinacalcet discussions will take place before this date.</p>	08/2016	On application	08/2017	<p>Specific</p> <p>Declare and participate</p>
		Direct financial	<p>Small private practice, sometimes seeing patients with primary hyperparathyroidism.</p> <ul style="list-style-type: none"> <li>- OP consultations identical to NHS</li> <li>- Payment per patient</li> <li>- 5-10% are PHPT patients</li> </ul>	2014	17/07/2017	Ongoing	<p>Specific</p> <p>Declare and participate.</p> <p>Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully.</p>

		Direct financial	Assisting patent solicitors in case involving cinacalcet and possible alternative calcimimetic drug. Calcimimetics are sometimes used in treating patients with primary hyperparathyroidism. Drug in very early stages of development.	01/2017	17/07/2017	01/2018	Non-specific Declare and participate
Imran Jawaid	Guideline Committee member	Direct financial	Professional and Linguistic Assessments Board (PLAB) Part 1 Panel Member General Medical Council (GMC) <i>(reimbursed travel and subsistence, receive a self employed locum fee)</i>	11/2017	On application	Ongoing	Non-specific Declare and participate
		Direct financial	Standing Member of the Guideline update committee A (NICE) <i>(reimbursed travel and subsistence receive a self employed locum fee)</i>	03/2016	On application	12/2017	Non-specific Declare and participate
		Direct financial	Associate Professor, Office of Medical Education, International University of Health and Welfare (IUHW) School of Medicine, Japan <i>(received travel, accommodation and fee for services)</i>	05/2017	On application	Ongoing	Non-specific Declare and participate
Jonathan Mant	Guideline Committee	Direct financial	Consultancy work for Expert-24: Communications	~2008	On	Ongoing	Non-specific

	Chair		company that manage a health web-site that provides information on life expectancy.		application		Declare and participate
		Indirect financial	NIHR Programme Grant for Applied Research Sub-panel Chair.	10/2016	On application	Ongoing	Non-specific Declare and participate
		Indirect financial	Holds grants as chief investigator awarded by NIHR.	2005	On application	Ongoing	Non-specific Declare and participate
Fausto Palazzo	Guideline Committee Member	Direct financial	Undertakes private practice - Private practice means that instead of being remunerated for surgery by the NHS the operation is paid for by an insurance company. The hourly rate paid by the NHS is considerably lower than that paid by an insurer. In every other respect: indications for surgery, surgical technique and follow-up surgery, my practice is identical. - Private surgery is paid on a fee for service basis. - I perform approximately 170 parathyroidectomies per year. Most of these are NHS patients, I do not know the exact percentage that are private but certainly less than half.	2005	17/07/2017	Ongoing	Specific  Based on the need for the committee member's expertise, in this instance NICE has confirmed that the individual can remain for discussion but participation is limited to responding to questions from the chair or other members.

		Direct non-financial	Co-author on US/UK reoperation guidelines. No payment received.	2016	17/07/2017	2017	Specific Declare and participate
		Indirect financial	Grant for HPT in pregnancy. The grant for HPT in pregnancy (now completed) and the autofluorescence in thyroid and parathyroid disease are paid to The Hammersmith Endocrine Surgical Research Fund. No personal direct or indirect salary or financial gain.	2015	17/07/2017	2017	Specific Declare and participate
		Indirect financial	Grant for fluoroscopy in hyperparathyroidism. No personal direct or indirect salary or financial gain.	2017	17/07/2017	2017	Specific Declare and participate
Peter Selby	Guideline committee member	-	None	-	-	-	-
Anthony Skene	Guideline Committee member	Indirect financial	Academic research in novel bone turnover markers in primary hyperparathyroidism. No financial interest, academic collaboration with Bournemouth University only.	On application	On application	Ongoing	Specific Declare and participate
		Direct financial	Undertakes private practice - My private practice reflects the scope of my NHS practice. - If referred I assess patients with potential PHPT and if	1994	11/09/2017	Ongoing	Specific Declare and participate. Private practice in this area



			<p>they reach the current criteria for surgery I offer them surgical parathyroidectomy.</p> <ul style="list-style-type: none"> <li>- I charge an individual professional fee for this advice.</li> <li>- PHPT patients constitute a small proportion of my private practice (less than 10%).</li> </ul>				<p>is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully.</p>
		Indirect financial	<p>Ethics Committee approval to open study on bone marker utilisation in PHPT. Likely to commence during guideline development (2018). An academic application only; no personal income received.</p>	01/02/2018	28/02/2018	01/02/2020	<p>Specific</p> <p>Declare and participate</p> <p>AS has submitted ethics committee approval for a novel bone marker RANKL. Our research recommendation is aimed at mainstream, conventional bone makers primarily used in osteoporosis.</p>
Nicholas Thomson	Guideline Committee member	-	None	-	-	-	-
Robert Cramb	Co-opted Guideline Committee member	Direct financial	<p>I have been a member of advisory boards and received speaker fees for the following drug companies for boards on lipid-lowering agents: Amgen, Agerion, Akcea, Novartis, Sanofi.</p>	On application	On application	On application	<p>Specific</p> <p>Declare and participate</p> <p>No action was taken as RC was not present at any meetings where calcimimetics were discussed.</p>

Catherine Williamson	Co-opted Guideline Committee member	-	None	-	-	-	-
----------------------	-------------------------------------	---	------	---	---	---	---

**GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER**

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.

Draft for consultation